An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study

被引：0

作者：

Flinn, Ian W. ^{[1
]}

Van der Jagt, Richard H. ^{[2
]}

Kahl, Brad S. ^{[3
]}

Wood, Peter ^{[4
]}

Hawkins, Tim E. ^{[5
]}

MacDonald, David ^{[6
,7
]}

Hertzberg, Mark ^{[8
]}

Kwan, Yiu-Lam ^{[9
]}

Simpson, David ^{[10
]}

Craig, Michael ^{[11
]}

Kolibaba, Kathryn ^{[12
]}

Issa, Samar ^{[13
]}

Munteanu, Mihaela C. ^{[14
]}

Clementi, Regina ^{[15
]}

Chen, Ling ^{[16
]}

Burke, John M. ^{[17
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Univ Ottawa, Canadian Leukemia Studies Grp, Ottawa Hosp, Ottawa, ON, Canada

[3] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[4] Princess Alexandra Hosp, Dept Hematol, Woolloongabba, Qld 4102, Australia

[5] Auckland Hosp, Auckland 1023, New Zealand

[6] QEII Hlth Sci, Hematol, Halifax, NS, Canada

[7] Capital Dist Hlth Author, Halifax, NS, Canada

[8] Westmead Hosp, Westmead, NSW, Australia

[9] Concord Repatriat Gen Hosp, Sydney, NSW 2139, Australia

[10] N Shore Hosp, Auckland, New Zealand

[11] W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA

[12] McKesson Specialty Hlth US Oncol Res, The Woodlands, TX USA

[13] Middlemore Hosp, Haematol Lymphoma Serv, Auckland 1640, New Zealand

[14] Teva Pharmaceut Ind Ltd, Clin Operat, Oncol & Immunol, Frazer, PA USA

[15] Teva Pharmaceut Ind Ltd, Amer Reg Clin Management, Global Clin Operat, Frazer, PA USA

[16] Teva Pharmaceut Ind Ltd, Biostat, Frazer, PA USA

[17] Rocky Mt Canc Ctr, Aurora, CO USA

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

902

引用

页数：3

共 50 条

[41] Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT).
Cavalli, Franco
Rooney, Brendan
Pei, Lixia
Van De Velde, Helgi
Robak, Tadeusz
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[42] EFFICACY AND SAFETY OF BENDAMUSTINE IN ASSOCIATION WITH RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH INDOLENT NON-HODGKIN LYMPHOMA OR MANTLE CELL LYMPHOMA
Cencini, E.
Fabbri, A.
Iannuzzi, A.
Schiattone, L.
Brambilla, C. Zuanelli
Bocchia, M.
HAEMATOLOGICA, 2017, 102 : 112 - 112
[43] Successful treatment of diffuse large B-cell non-Hodgkin lymphoma with modified CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy and rituximab in a patient with Nijmegen syndrome
Dumic, Miroslav
Radman, Ivo
Krnic, Nevena
Nola, Marin
Kusec, Rajko
Begovic, Davor
Labar, Boris
Rados, Marko
CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (09) : 590 - 593
[44] Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma:: results of a randomised phase III trial (OSHO# 19)
Herold, M
Schulze, A
Niederwieser, D
Franke, A
Fricke, HJ
Richter, P
Freund, M
Ismer, B
Dachselt, K
Boewer, C
Schirmer, V
Weniger, J
Pasold, R
Winkelmann, C
Klinkenstein, C
Schulze, M
Arzberger, H
Bremer, K
Hahnfeld, S
Schwarzer, A
Müller, C
Müller, C
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2006, 132 (02) : 105 - 112
[45] Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study
Flowers, Christopher
Tilly, Herve
Morschhauser, Franck
Sehn, Laurie H.
Friedberg, Jonathan W.
Trneny, Marek
Sharman, Jeff P.
Herbaux, Charles
Burke, John M.
Matasar, Matthew
Rai, Shinya
Izutsu, Koji
Mehta-Shah, Neha
Oberic, Lucie
Chauchet, Adrien
Jurczak, Wojciech
Song, Yuqin
Greil, Richard
Mykhalska, Larysa
Bergua-Burgues, Juan Miguel
Cheung, Matthew C.
Pinto, Antonio
Shin, Ho-Jin
Hapgood, Greg
Munhoz, Eduardo
Abrisqueta, Pau
Gau, Jyh-Pyng
Hirata, Jamie
Jiang, Yanwen
Yan, Mark
Lee, Calvin
Salles, Gilles
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S358 - S359
[46] R-COMP 21 (Prednisone, Cyclophosphamide, Vincristine, Myocet™ and rituximab) for frail and elderly patients with aggressive B-Cell non-Hodgkin lymphoma:: A pilot study
Isidori, Alessandro
Ferrara, Felicetto
Alesiani, Francesco
Ronconi, Sonia
Catarini, Massimo
D'Adamo, Francesca
Guiducci, Barbara
Bernardi, Daniele
Visani, Giuseppe
BLOOD, 2007, 110 (11) : 180B - 180B
[47] The cost-effectiveness of rituximab, cyclophosphamide, vincristine and prednisolone (RCVP) compared with CVP for the treatment of follicular non-Hodgkin's lymphoma (NHL) in the UK.
Lewis, Gavin
Marcus, Robert E.
Proctor, Stephen J.
Gyldmark, Marlene
Creeden, James
Aultman, Rick
Jost, Fred
BLOOD, 2006, 108 (11) : 107A - 107A
[48] Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
Friedberg, Jonathan W.
Thompson, Carrie A.
Trneny, Marek
Morschhauser, Franck
Salles, Gilles
Reagan, Patrick M.
Hertzberg, Mark
Smolewski, Piotr
Zhang, Huilai
Thieblemont, Catherine
Hu, Bei
Fonseca, Gustavo
Kim, Won-Seog
Martelli, Maurizio
Mehta, Amitkumar
Campinha-Bacote, Avrita
Yan, Mark
Hirata, Jamie
Sugidono, Matthew
Lee, Calvin
Sharman, Jeff P.
BLOOD, 2022, 140 : 6623 - 6626
[49] Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study In Treatment-Naive Patients With CD20-Positive B-Cell Non-Hodgkin's Lymphoma (NHL)
Younes, Anas
Flinn, Ian
Berdeja, Jesus
Friedberg, Jonathan W.
Casulo, Carla
Thieblemont, Catherine
Morschhauser, Franck
Westin, Jason R.
Seetharam, Shobha
Hellemans, Peter
Smit, Hans
de Vries, Ronald
Dauphinee, Elisa
Badamo-Dotzis, Julie
Fourneau, Nele
Oki, Yasuhiro
BLOOD, 2013, 122 (21)
[50] Updated Results of the Phase III Study of First-Line Bendamustine/Rituximab Versus CHOP plus Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
不详
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (02) : 128 - 129

← 1 2 3 4 5 →